Microplate Dx Limited
- 12/09/2023
- Seed
- $3,117,000
Microplate Dx Limited specialises in rapid antibiotic susceptibility testing diagnostics, enabling clinicians, at the point-of-care, to confidently select the best choice of antibiotic to treat a patient’s infection in a matter of minutes, significantly quicker than the current gold standard technology which takes at least 2 days. Our award-wining, platform diagnostic test helps reduce the major global health threat of antimicrobial resistance and ultimately, saves lives.
- Industry Medical Equipment Manufacturing
- Website https://microplatedx.com/
- LinkedIn https://www.linkedin.com/company/microplate-dx-limited/about/
Related People
Stuart HannahFounder
CEO - Microplate Dx Limited.
Developing a rapid, cost-effective, direct-from-sample, antibiotic susceptibility test, which quickly identifies the best choice of antibiotic for a particular infection in minutes, significantly quicker than the current gold standard of days.